Ligand Pharmaceuticals

Ligand Pharmaceuticals (LGND): Lemelson Reaffirms 0 PT

Marlborough, MA, June 24, 2014 -- Lemelson Capital Management, a private investment management firm, today reaffirmed the analysis presented in its 25-page research report on Ligand Pharmaceuticals Inc. (NASDAQ:LGND), released originally on June 16, 2014, and the projected price target for its shares.

Correction in Ligand Pharmaceuticals' shares
”Despite nearly 16% correction in Ligand Pharmaceuticals Inc. (NASDAQ:LGND) shares since the report was published six trading days ago, we continue to affirm that the intrinsic value of its shares is immaterial,” said Lemelson Capital Management . . .


This content is exclusively for paying members. Access all of our content on including years of timeless investment news and in depth analysis for only a few dollars a month by signing up here while also supporting quality content and journalism, or learn more about our premium content here

If you are subscribed and having an account error please clear cache and then cookies if that does not work email or click chat button and we will get back to you as quick as humanly possible

Saved Articles

Subscribe to our mailing list

* indicates required

Opt out of occasional 3rd party offers